The article provides data on modern approaches to the treatment of patients with severe uncontrolled bronchial asthma with an emphasis on the use of dupilumab, a human recombinant monoclonal antibody to the alpha subunit of the interleukin (IL)-4 receptor, which inhibits signal transmission from both IL-4 and IL-13.The results of dupilumab pivotal randomized tennessee titans dog bandana clinical trials DRI12544, QUEST and VENTURE are summarized.Indications for use of this medicinal product are listed in Federal Clinical Guidelines on the management of asthma (year of revision 2019).Clinical cases with various clinical course of bronchial asthma are described, including cases with frequent exacerbations.
In conclusion, dupilumab could be a treatment of choice for the patients with severe bronchial asthma and hindirochakkahaniya.com it is reasonable from an economic, clinical and pathogenetic point of view.